ALK and neuroblastoma: In ALK-addicted neuroblastoma cells, integrated proximal proteomics studies identified SHP2 as a direct interactor of ALK phospho-tyrosine residues, with further validation revealing that SHP2 activation and subsequent protein–protein interaction is abrogated upon ALK inhibition following ALK-TKI treatment (27, 60).